CaHA Injectable for Facial Use Gains Regulatory Approval in China
The approval makes it the first calcium hydroxylapatite microsphere injectable product approved in China for facial soft tissue augmentation, according to the company.
The approval makes it the first calcium hydroxylapatite microsphere injectable product approved in China for facial soft tissue augmentation, according to the company.
The injectable, known as Restylane Contour in the US, achieved a 94.4% responder rate at six months, with improvements sustained through 12 months.